-
| ISIN | US82933R1005 |
|---|---|
| Sector | Healthcare |
| Exchange | NASDAQ |
| CurrencyCode | USD |
| Industry | Medical Instruments & Supplies |
| Market Cap | 51M |
|---|---|
| PE Ratio | None |
| Target Price | 12.45 |
| Beta | 1.83 |
| Dividend Yield | None |
Singular Genomics Systems, Inc., a life science technology company, develops next generation sequencing and spatial multiomics technology for researchers and clinicians to advance science and medicine. It is involved in the developing of G4, consisting of G4 instrument and associated consumables for various applications, such as max read kits for single cell sequencing, rare variant detection with high-definition sequencing, gene fusion detection with ring-seq, and extended range sequencing; and PX instrument and associated consumables focusing on the single cell and spatial analysis markets. The company was incorporated in 2016 and is based in San Diego, California. As of February 21, 2025, Singular Genomics Systems, Inc. was taken private.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for OMIC using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025